11

CURRICULUM VITAE

QUALIFICATIONS

Mb ChB MRCP MD FRCR

CURRENT POSITION

Visiting Professor Cranfield University Consultant Clinical Oncologist

Bedford and Addenbrooke’s Cambridge University NHS Trusts

Professor Robert J Thomas

22

INDEX

Page

PERSONAL DETAILS 3

CONTACT INFORMATION 3

PRIZES AND AWARDS 3

PRESENT APPOINTMENT 4

POSTGRADUATE POSITIONS 4

MANAGEMENT AND AUDIT EXPERIENCE 5-6

RESEARCH 6-8

TEACHING 8

INVITED LECTURES 9-10

MEDIA EXPERIENCE 10

OTHER INTERESTS 10

PUBLICATIONS 11 – 22

33

PERSONAL DETAILS Address for correspondence Department of Oncology

Box 193, Addenbrooke’s Hospital Cambridge CB2 2QQ

Communication Mobile 0771 5110919 Work (Mon, Thurs, Fri) 01234 792 274 Work (Tues, Wed) 01223 274485 Fax. (Work) 01234 792 668 Website www.cancernet.co.uk Emails: rt@cancernet.co.uk Twitter cancernet@cancernetuk

robert.thomas@addenbrookes.nhs.uk robert.thomas@bedfordhospital.nhs.uk

Personal details Born 16th July l961 Married, two sons19 & 15 years, daughter 3 years Qualifications Mb ChB University of Leicester, 1984. MRCP 1988. FRCP 2001 FRCR 1992-2010. MD Institute of Cancer 1995. Visiting chair Cranfield University 2007 Clinical teacher Cambridge University 2008 Certification numbers GMC: 2917443 MPS: 251353 Arsac: 23888 Prizes

Roche, MD Anderson, BOA Junior clinical research prize 1994.

The Northwest travelling fellowship 1995.

BUPA Foundation communication prize 1999

BUPA foundation communication sponsorship award 1999

BMA book prize for patient information 1999

BMA video prize 2000

Hospital Doctor Magazine innovation category winner 2000

Hospital Doctor Magazine Doctor of the year 2000/1

Law Society Rugby Club Player of the year 2005

NHS communication research prize 2001

British Oncology Association, Oncologist of the year 2006/7

44

PRESENT APPOINTMENT

Addenbrooke's Hospital Cambridge University NHS Trust, two days a week, treating

patients with intensity modulated, image guided and conformal radiotherapy, tomotherapy

and I125

bracytherapy, participating in quality assurance, patient safety and audit

programmes. The post also involves teaching undergraduate medical students, in the role of

formal clinical teacher, and participating in the postgraduate lecture educational series.

Bedford Hospital NHS Trust, three days a week, managing NHS and private patients with

oncological emergencies, chemotherapy, biological, hormone and interventional therapies.

The post involves being clinical, chemotherapy and research leads. Specialist interests,

originally included lymphoma, Hogkin’s Disease, upper GI, lung and brain cancers but now

multidisciplinary management is confined to urological, breast, skin and lower GI

malignancies.

Visiting professor Cranfield University, involving formal lectures, supervision of Msc and

PhD translational medicine and health economic students.

POSTGRADUATE APPOINTMENTS

House Officer and Senior House Officer Rotations 1.8.84 to 31.7.1987

Leicester, Derby Hospitals and Nottingham Hospitals

General and Medical Oncology Registrar 1.08.87 to 1.10.88

The Lister Hospital, Stevenage.

Clinical Oncology Registrar Rotations 1.10.88 to 13.01.92

Mount Vernon, Middlesex and Royal Free Hospitals

Research Fellow / Honarary Senior registrar 15.11.92 to 28.2.94

The National Hospital, Institute of Neurology, Queen Square.

The Royal Marsden, Institute of Cancer Research.

Clinical Oncology Senior Registrar Rotation 1.03.94 to 1.8.96

The Royal Marsden Hospitals.

Clinical Oncology Consultant 1.8.96 to present Addenbrooke's and Bedford Hospitals Cambridge University Trusts

55

MANAGEMENT AND AUDIT EXPERIENCE

The Primrose Ocology Unit: As clinical and chemotherapy lead I have been responsible

for succesfully establishing Multidiscipinary Teams both locally and linking closely with

network colleagues. This has resulted in highly praised, succesfull peer reviews across all

cancer types. Over the last 10 years, new patient numbers have increased from 223 to >900

per year. Patients were originally managed in a porta cabin but following a £3 million

charitable campaign, they now attend a state of the art designated cancer unit. Patient

satisfaction, audited once a year, has increased from 31% to 98% on local and national

audits. Over 50 other clinical audits have been completed ensuring departmental and

individal adherance to national guidelines and best practice.

Shifting the paradign of inpatient to outpatient care. I have established a rapid access

pleural or peritoneal aspiration service using a validated outpatient technique (Thomas palliative

care ‘93). Patients with hypercalcaemia, uncompliacted dehydration, septacaemia or vomiting

are given fluids, antibiotics and other medication as a day case until recovery – significantly

reducing admission rates, cost for the trust and inconvenience for the patients.

Introducing I125

prostate brachytherapy: Clinical lead for the development of low dose

rate prostate brachytherapy for the Anglia Cancer Network based at Addenbrooke’s

Hospital. This involved working closely with a multidisciplinary team, local charities and

competitive tending to commissioners. Since 2008, we have sucessfully treated over 400

patients with only 2 men experienceing a biochemical relapse. Our audits of toxicty and post

treatment dosimetry have exceeded international standards.

Clinical guidelines: Network guideline lead for erythropoietin, anaemia lymphoma (2001)

and Urological malignancies from 2003 - 2005. I wrote and maintained the Bedford

guidelines for breast, urology and Gastro-intestinal cancers, chemotherapy, and emergency

procedures.

Improving treatment information and survivourship strategies. A working group was

established to evaluate patient’s needs, design and evaluate local programmes including:

1. A preparatory film made with Sue Lawley & Anton Rodgers translated into 6 other UK

ethnic languages following a £100,000 NOF grant. It was the official video for Cancer Bacup

and it’s randomised evaluation won the national NHS communication prize.

66

2. A personalised hand-held information file given to all patients containing bespoke

information at the relavant stage of the cancer journey – this file won a BMA book prize.

3. A lifestyle exit tool box for every patient involving a formal survivourship interview,

supported by bespoke written lifestyle information and routine referral, if required, to

dieticians, smoking cessation clinics and personal trainers in local municipal gyms.

4. A patient/professional cancer information and survivourship web site (Cancernet.co.uk)

attracting 87,000 users per month containing >600 peer reviewed specific information sheets

designed to be downloaded for the hand held file. Other practical resources designed help

survivours and their families are updated by a team of patients and health profesionals.

Development of a national cancer exercise referral scheme; Working with the leisure

industry and Macmillan Cancer Support I wrote the national standards for a “Skills Active”

approved level 4 cancer rehabilitation course (July 2010). Since then, I formed a partnership

with training organsiations, including Virgin Active, to train over 100 exercise professionals

across the UK, allowing them to receive referrals for exercise rehabilitation (All Bedford

patients are considered for an exercise referral – an audit demostrated a 65% uptake rate).

Other national experience: Editorial member of the 1998 National Cancer Plan. Editorial

member of the NICE guidance on supportive care. Oncology Lead for the DoH working

party for Complementary Medicines. Member of the NCRN complementary medicine sub

committee. Editorial member of the Journals; Focus on Cancer Medicine, British Journal of

Cancer Management; Healthcare at home and British Journal of Medical Practice. Editor for

the evidence review for the role of lifestyle for the National self help and suvivorship

committee. Current member of the Macmillan late effects steering committee and Chair of

the National Survivorship exerpert Advisory Committee and the “walking for Health”

Committee. Patron of the national conference of self help groups.

International experince. Advisor for National Cancer Institute of Mexico patient

informationa and author of their patient information manual.

RESEARCH

Links have been established with the Institute of Public Health, Cambridge University;

Cranfield University, Cranfield Business School and the Universities of Bedfordshire and

Hull. A research manager is funded from prizes, grants and pharmaceutical trials, and the

two research nurses are funded by the NCRN. Through a series of motivational “away day

77

meetings” we have managed to created a culture which empowers all the staff in the

Primrose unit take a pride in research activities . Six out of the 10 regular nurses and even

one of our receptionists, have presented work at international conferences. In the last 10

years 38% of our patients have been involved in clinical studies, 870 in prospective or

randomised studies and a further 2200 in retrospective or questionnaire surveys.

Pharmaceutical trials – Our research unit was the highest recruiter in 3 out of 4 national

and European randomised studies (Janssen Cilag, Orthobiotec, Novartis & Roche).

National Cancer Research Network approved trials – Local chief investigator for the

prostate RTO1 conformal radiotherapy trial at Addenbrooke’s and enterd 60 patients into the

national CHiPP dose fractionation radiotherapy trial. At Bedford in the last three years I have

recruited over 200 patients into the national Diet and Breast cancer study (the UK’s highest),

80 into the Institute of Cancer Research Prostate Genetics Study and 203 into the National

Pomi-T trial as well as several other NCRN approved studies.

Locally designed, randomised or prospective studies (completed and published)

- a RCT comparing a patient information tool versus standard care;

- a cross over RCT comparing two aromatase inhibitor drugs for breast cancer;

- a phase 2 study assessing a novel COX-2 agent;

- a prospective study of Qol and patient preference between tamoxifen and letrozole;

- a prospective study of Qol and patient preference between tamoxifen and exemestane;

- a double blind RCT comparing a mineral/vitamin supplement with placebo in men with

prostate cancer (NCRN adopted).

- A double blind RCT comparing an antioxidant /polyphenol rich food supplement (Pomi-T)

with placebo in men with prostate cancer (NCRN adopted).

Health economic studies. Working with Cranfield international busines school, we have

conducted the first cost assessment of a breast cancer relapse to include both the Hospital

and Community activities. Working with the health economics team of Sanofi Aventis,

Astrazeneca and Pfizer we have helped with the health economic assessment of adjuvant

drugs for breast cancer for NICE technology submissions.

Current laboratory research We are currently identifying triple negative patients from our

breast cancer data base, analysing tissue blocks for androgen receptor status and are now

applying for funds to expand this work into a Phd project.

88

National Research imput I regularly advise the scientific committees of 5 pharma

companies, peer review grant proposals for Scottish NHS executive and National Cancer

Research Committee, am regular assessor for a number of medical journals.

Research funding in current post

Hospital Doctor magazine 2000/1 Innovation winners grant - £5,000

Hospital Doctor magazine 2000/1 overall winners grant - £5,000

Bupa Foundation Educational award 2000 - £10,000

Educational grant from Novartis pharmaceuticals 2002 - £45,000

Educational grant from Amgen pharmaceuticals - £10,000

Educational Grant from IVY Medical Chemicals 2002 - £37,000

Educational grant from Cambridge Laboratories Ltd 2004 - £65,000

New Opportunities Fund (Lottery) Grant - 2001 - £100,000.

Further unrestricted Educational grant from Novartis pharmaceutics 2003 - £35,000

Unrestricted Educational grant from Pfizer pharmaceutics 2005 - £65,000

Panaceas Society Research grant 2007-9 - £24,000

Mercedes charitable research award 2010 - £16,000

Wright Foundation Research award 2011 - £10,000

Prostate Action Peer reveiwed research grant -£10,000

TEACHING

Medical students: I designed and implemented a timetable for the 40 Cambridge & UCH

students who attended Bedford from 1998-2002. This included organising the appraisal of

students, auditing their satisfaction, attending meetings with assessors in Cambridge

University and University College Hospital London. As a formal “Recognised Clinical

Teacher” for Cambridge University I teach medical students weekly and have scored

"outstanding teacher nominations" from every student for the last three years.

Junior Doctors; I teach publishing techniques and work with junior doctors to help them

publish editorials in national journals.

Post graduate students. Following the appointment of visiting professor at Cranfield

University I now teach on their transactional medicine course. I have supervised six MSC

students and a PhD post graduate.

Past experience: Teaching co-ordinator at The Middlesex Hospital & The Royal Free

Hospitals. Regular tutor on the Middlesex Hospital MRCP course. At the Royal Marsden

Hospital I taught medical students on a weekly basis from St George's Medical School and

gave regular tutorials in the in-house FRCR and Nursing Msc course.

99

INVITED LECTURES

National:

The International Science Festival, Edinburgh. 1995.

The Royal Free Hospital (Neuro-Oncology), July '93 & September '95.

The Institute of Psychiatry (Radiobiology) January '94.

The National Hospital for Neurology (Neuro-Oncology), March '94.

St Lukes Hospital, Guilford (High dose chemotherapy), October '95.

Royal College of Radiologist annual conference 1994, Warwich. (Neuro-Oncology), '94.

Cancer Update (Seminoma). RMH, July '95.

Cambridge University – Clinical research 1997

Breast cancer symposium – Cholester 1998

Cancer Bacup – Improving in formation for patients in practice 1998

Edingburgh University / Western General – Fatigue and Chemotherapy 1998

Cardiff , Birmingham & Manchester – Anaemia and fatigue 1998-9

Royal College of Physicians – Anaemia and fatigue 1999

Royal College of Pathologist – Cost effectiveness of Gcsf in clinical practice 1999

Marie Curie – National symposium on information for Patients 1999

Mount vernon, UK National symposium on information for Patients Jan 2002

Cambridge University Annual Cancer Lecture 2004

Breast cancer symposium Cambridge – Cost effectiveness of Aromatase inhibitors 2005

Guest of Honour speech University of Bedfordshire graduation ceremony 2008.

Cambridge University Research lecture 2009

British leisure induxtry annual conference – evidence for exercise after cancer 2010

Vendre, Cardiff Lifestyle and Cancer, 2010

Harrogate - Network Annual Breast Cancer symposium 2010

Penny Brohn Cancer Care – Annual survivorship conference 2010

Biolab annual conference (Nutritional testing and cancer) 2011

London Oncology Clinic, Live strong programme 2010 and 2011

Southampton Prostate survivorship group – Evidence for lifestyle after Cancer 2011

Cambridge Prostate Survivorship group - Evidence for lifestyle after Cancer 2011

National Conference of Cancer Self Help Groups annual conference Manchester 2011

Wright Foundation/fitness industry Annual conference Birmingham 2011

Norfolk Prostate Cancer Survivorship Meeting 2011

Lancashire annual Cancer Network conference Preston 2011

Bone Academy annual conference London 2011

Macmillan Primary Care Conference, Lords Cricket Ground 2011

Flitwich Survivorship Meeting Oct 2011

Yorkshire Cancer Network Annual conference 2011

National mammographia conference (Harrogate) 2011

London Oncology Clinic Survivorship programme Feb 2012

Lancaster Cancer Network cancer update conference Feb 2012

Royal Marsden Hospital survivorship for professionals conference Feb 2012

The National Mesothelioma society annual conference Oct 2012

London Mammographia Conference Oct 2012

Penny Brohn annual survivourship lecture Nov 2012

Yes for Life lecture – polyphenols and Cancer Nov 2012

Lanchashire Cancer Network annual conference Dec 2012

Worchester Prostate Cancer Survivourship annual conference Feb 2013

1100

Cancerpartners UK survivourship lecture Elstree Feb 2013

Bristol Mesothelioma Group annual conference Feb 2013

Bagnall centre survivourship lecture and debate Feb 2013

International:

Memorial Sloane Kettering Hospital, New York, USA, 1994

Duke University Medical Centre, North Carolina February 1996.

Amgen symposium Atlanta USA (ASCO) 1999

Melbourne, Australia (COSA) Treating anaemia in oncology – 1999

Ischia, Italy. International symposium on information for Patients Nov 2000

Morelia, Mexican Annual Cancer Conference - Optimising raltitrexed use Nov 2001

Orlando USA – Novartis symposium (ASCO) – Patient choice and AI’s May 2002

Sao Paulo, Brazil – Novartis symposium – Qol issues and AI’s June 2002

Athens – Novartis symposium – Qol & choice in breast cancer management 2004

National Hospital of Mexico – Benefits of patient information 2007

National Hospital of Mexico – Cost effectiveness in adjuvant drug development 2008

MEDIA EXPERIENCE

Media Training: London Studios 2001 and 2004

Documentaries: London Tonight’01, Pamorama ‘06, Horizon 2007. The Food Hospital ‘11

Information and promotional films: Macmillan exercise campaign website film (2011), Radiotherapy and chemotherapy patient information film (2000 and 2005).

Live TV interviews: BBC Newsnight 2008 (Jeremy Paxman), BBC breaskfast news 2011

Live Radio: Jeremy Vine show 2009, Radio Europe (Panel discussion 2009) The Today programme( Radio 4) 2011, Radio Swindon 2010, Radio Wales 2011. Plus numerous news interviews for local radio stations (BBC Cambridge, Bedfordshire)

Media spokesperson: Macmillan Cancer support and advisor for the Channel Four programme” The Food Doctor”

OTHER INTERESTS

Sport: Rugby - Welsh Boys Club Cap, Captain School 1st XV, Captain of the University 1st XV. Surrey league until May 2008. Now enjoying tennis, aerobics, gym, windsurfing, skiing, running and generally keeping fit.

Fund raising and charity work: Charity Balls; The London Marathon, The World Medical Games; Carol services and annual exhibitions including The Young Farmers Club. Board Member of Casting for Life and Patron of The National Conference of Self Help charities, Chair of the Ramblers / Macmillan advisory group .

1111

PUBLICATIONS

Original clinical research (Lead investigator and first author) What size chest tube for pleural effusions? Robert Thomas, Stephen Sagar. British Journal of Hospital Medicine (l990). Vol 43. p.53. An analysis of surveillance for stage one combined teratoma/seminoma of the testis. Thomas R, Dearnaley D, Horwich A. British Journal of Cancer (1996), vol 74, pp 59-63. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. R Thomas, N James, D Guerro, S Asley, A Gregor, M Brada. Radiotherapy & Oncology (1995). Vol 33, pp.113-116. Speech and language disorders in patients with high grade gliomas and its influence on survival. R Thomas, M O'Conner, S Ashley, M Brada. Journal of Neuro-Oncology (1995). Vol.23: p.265-270. Pneumothorax and palliative pleural aspiration - an audit of technique. Robert Thomas, J Maher. Palliative Medicine (1993): 7: pp 67-71. Metastatic Parathyroid Carcinoma. Robert Thomas, Ana Cassoni. Journal of the Royal Society of Medicine (1992). 85(3) 92;182. Modifying the Barthel performance index score for use with patients with brain tumours. R.Thomas D Guerrero, F Hines, M Brada. European Journal of Cancer Care (1995) Vol.4, pp. 63-68. Modifying the Barthel index for use in patients with brain tumours - an update. R Thomas. European Journal of Cancer Care (1997). Vol.7, pp 62-7. Distribution kinetics of radiolabelled monoclonal antibodies in experimental tumours following interstitial and systemic administration. R Thomas, P Carnochan, M Brada - Radioactive isotopes in Nuclear Medicine and Research (1994). pp 56-82. Patients preferences for video cassette recorded information. Effect of age, sex and ethnic group. Thomas R, Deary A, Kaminski E, D Stockton, N De Zeeuw. The European Journal of Cancer Care (1999). Vol 8 pp 23-27. Forewarned is forearmed – benefits of preparatory information on video casette for patients receiving chemotherapy and radiotherapy - a randomised controlled trial. Thomas R, Daly M, Perryman B, Stockton D European Journal Cancer (2000), issue 36 1536-1543. Lessons Learnt from Raltitrexed – Quality Assurance, Patient Education and Intensive Supportive Drugs to Optimize Tolerability. R.Thomas, M. Williams, J. Garcia-Vargas Clinical Oncology (2003) 00:1-6. Examining quality of life issues in relation to endocrine therapy for breast cancer. Robert Thomas. American Journal of Clinical Oncology (2003). Vol. 26, No. 4, pp S40-S44

1122

Measuring information strategies in oncology – developing an information satisfaction questionnaire. Thomas R, Kaminski E, Stanton E and Williams M. European Journal of Cancer Care (2004), 13, 65-70. Giving patients a choice improves quality of life: A multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. R. Thomas, A. Makris, D. Bloomfield, A.M. Moody, M. Williams. Clinical Oncology (2004) 16: 485-491. Dietary advice combined with a salicylate mineral and vitamin supplement has some tumour static properties - a phase II study. R Thomas, M Blades, M Williams and S Godward. Nutrition & Food Science (2005), Volume 35 Issue 6, 436- 451 Can switching to Aromatase inhibitors in tamoxifen intolerant post menopausal women improve hot flushes, qol and mood? R Thomas, C Marshall, M Williams, L Walker Bristish Journal of Cancer ((2008) 98, 1494-1499 The financial implications of switching to adjuvant exemestane in patients with early breast cancer. RJ Thomas, M Williams, C Marshall, J Glen & M Callam. Clinical Focus Cancer Medicine (2009); 1(3):82–87. Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer. Thomas R, Glen J, Marshal C Breast Cancer Research and Treatment (2009); Volume 117 Issue 2 page 289. A randomised double-blind phase II study of lifestyle counselling and salicylate compounds in patients with progressive prostate cancer. R Thomas, R Oakes, J Gordon, S Russell, M Blades and M Williams (2009) Nutrition & Food Science, 39(3):295 – 305. The total hospital and community UK costs of managing patients with relapsed breast cancer. RJ Thomas, M Williams, C Marshall, J Glen and M Callam (2010) British Journal of Cancer, 100, 598 – 600. A prospective survey of chapped lips and cold sores during chemotherapy. R Thomas, T Taylor, M Williams. Focus on Cancer Medicine (2010); 2 (1) 3-7. Lifestyle factors correlate with the risk of late pelvic symptoms after prostatic radiotherapy. R Thomas, M Holm, P Bellamy, A Jervoise, J Maher Clinical Oncology (2013) April

Editorials Endometrial carcinoma - Adjuvant locoregional therapy. Robert J Thomas, Peter Blake. Clinical Oncology. 1996 8: 140-146. Patient Information materials in Oncology: Are they needed and do they work? Thomas R, and H Thorton. Clinical Oncology 1999;11: 225-231 How to deal with the complexities of patient consent? Robert Thomas. Pulse Clinical pp42-43, 2003. The changing face of informed consent. R Thomas. British Journal of Cancer Management. 2004 Vol. 1 No. 1. pp 11-15.

1133

What are the costs of not using rhEPO to treat anaemia in cancer. R Thomas. Focus on anaemia in cancer. 2002, Vol 3, issue 2, pp52-53. NICE guidance on supportive and palliative care – Implications for Oncology Teams. Dr R Thomas and Professor Alison Richardson. Clinical Oncology (2004) 16: 420-424. The NICE guidance on supportive and palliative care. Dr Robert Thomas and Professor Alison Richardson. British Journal of Cancer Management (2004); Vol. 1 No. 3. Restructuring supportive care – Affect on oncology practice. R Thomas. British Journal of Cancer Management (2005); Vol.2 No.4.p12-15 Anaemia, fatigue and Epoeitin in Oncology R Thomas. British Journal of Cancer Management. (2005) Vol.2 April No. 4,. Complemenatry and alternative medicine evidence online for cancer. J Richardson, K Pilkington and R Thomas. BJCM 2005, vol.2, no.2, pp10-12. Diet, salicylates and their effect on prostate cancer. 2006. Robert Thomas, Cathryn woodward and Peter Williams. Brtitish Journal of Cancer Management voume 3, 1, pp 5-9. Adjuvant breast cancer drugs- blockbusters or bankrupters. 2006 , Thomas R, Glen J, Callam M, British Journal of Cancer Management no.3, vol 24, pp 5-9 Can dietary and lifestyle intervention alter prostate cancer progresssion. 2007. Robert Thomas, Mabel Blades, Madeleine Williams. Nutrition & Food Science, 2007 vol 37, no.1 pp 24-36. Cancer – the roles of exercise in prevention and progression. Robert Thomas and Nichola Davies. Nutrition and Food Science 2007.Volume 37 Issue 5 Lifestyle during and after cancer Treatments Thomas R, Davies N. Clinical Oncology 2007, 19, pp 616-627. Should oncology units establish Lifestyle Clinics?. Thomas R, Williams M, Davis N. Clinical Focus on Cancer Medicine 2009 (1) 2 38-48 Life after cancer – rehabilitation at home can improve well-being and survival. R Thomas, M Williams and T Taylor (2009) British Journal of Home Healthcare, 5(1):10-12. Exercise after Cancer – How to do it? R Thomas. ICAN Journal September 2009 Exercise and lifetsyle after cancer – evidence review Davis N, Bateman L, Thomas R British Journal of Cancer (2011) vol 105 pp 52-73. Breast Cancer – a review of the latest trials from ASCO R Thomas and M Holm ICAN 2013 Polyphenols and Cancer R Thomas ICAN 2013

1144

Letters and case reports with literature review

Writing medical Papers . Dr Robert J Thomas. Journal of The Royal Society of Medicine August 1993 Evidenced based patient information - Local policies would be better than a national strategy. 1999, British Medical Journal, vol 318. page 462. Further differential diagnosis of hilar masses. Dr Robert J Thomas. The British Journal of Radiology (1992). Vol.65, No.774, p.553. Mistaken Hilar Mass. Dr Robert J Thomas, Dr G Duchesne. The British Journal of Radiology (1991). Vol.64, No.766, p.977-978. The Tin-Tack sign in post irradiation scalp skin scales. Dr Robert J Thomas, Dr Neil Smith, Dr Margaret Spittle. British Journal of Dermatology (1992). Vol 126/1: 90 PET saves man. Robert Thomas, Madeleine Williams & Sally Old. British Journal of Cancer Management. Summer 2004 Vol. 1 No. 1, p22-23 Bevacizumab saves the day. R Thomas, Sanjay Raj, Ahmed Eldin. 2005. BJCM. Vol.2, number 2. p20-21. Cetuximab – a new team player. Yassa Haba, Myrddin Rees, David Skipper, Robert Thomas. 2006 BJCN, vol 2, no.3 pp19-21. A cool solution for docotaxel induced onycholysis: A case report of cold water baths to prevent docetaxel induced onycolysis PM Ding RJ Thomas Clinical focus on Cancer Medicine 2010 2(1): 18-19.

Original research (not first author) Olfactory sensations produced by high-energy photon irradiation of the olfactory receptor mucosa in humans. Stephen Sagar, Robert J Thomas, L. Loverock, Margaret Spittle. International Journal Radiation Oncology Biology Physics (1990). Vol 20, pp 771-776. Dosimetry of intralesional 131I monoclonal antibody therapy in patients with recurrent high grade glioma. S. Chittenden, R. Thomas, G. Flux, T. Smith, M. Brada, M. Flower, R. Ott. 1995. (1). pp. 270-274. Mathematical modelling of 3D intracranial radioisotope dose distribution. G Flux, R Thomas, R Ott, Eur. J. Nuclear Medicine. published July 1997 The verbally administered barthel index in patients with glioma. Dr L Brazil , Dr R Thomas, Dr M Brada. Radiation and Oncology, July 1995. The Role and Activity of an Italian Volunteer Organisation providing Information and Emotional Support for Patients with Cancer. F. De lorenzo, c. Paglia i. Duce and U. Tirelli, R. Thomas,. G. Vecchio. Dipartimento di Biologia e Patologia Cellulare e Molecolare L. Califano, Universita Federico Napoli. Nov '98. Health communications June 1999..

1155

An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. C. Rose, O. Vtoraya, A. Pluzanska, N. Davidson, M. Gershanovich, R. Thomas, S. Johnson, et al. European Journal of Cancer 39 (2003) 2318-2327 To what extent does neutropenia impact on the ability to deliver planned chemotherapy in lymphoma? – The results of a UK neutropenia audit J Sweetenhama;B Hancockb; R Pettengellc; A Pagliucad; R Thomase; P Hoskins; A McMillang; M Joynerh; D Spooneri. British Journal of Cancer 2004 vol 23. pp12-17. Complementary and Alternative Medicine Evidence On-Line (CAMEOL) For Cancer J Richardson, K Pilkington & Robert Thomas. Bristish Journal of Cancer Management December 2005, Volume 5. Aloe Vera for preventing radiation-induced skin reaction: A systemic literature review. J Richardson, J Smith, M McIntyre, R Thomas, K Pilkington. Clinical Oncology. 2005, 17:478-484. Empowering patients to make informed decisions by measuring their needs and satisfaction 2007 N Davies, R Thomas Clinical Focus Cancer Medicine vol 1 (issue1) pages 3-8.

Online Journals

Black Cohosh for menopausal symptoms in women with breast cancer: A systematic literature review. Joanna Smith, Janet Richardson, Michael McIntyre, Rob Thomas, Karen Pilkington. http://rccm-host.wmin.ac.uk/cameo/ Davies, N.J., Kinman, G., Thomas, R.J., and Bailey, T.A. (2008) Information satisfaction in breast and prostate cancer patients: Implications for quality of life. Psycho-Oncology, published online

Books

Simple tips for a happy family – reducing arguments by Robert Thomas (a guide for patients and their families during times of stress such as after a diagnosis of cancer – Health Education Publications 2008 Lifestyle after cancer – the facts by Robert Thomas 2008. – Health Education Publications (www.cancernet.co.uk/books.htm) Lifestyle and cancer – the facts by Robert Thomas 2011. – Health Education Publications (www.cancernet.co.uk/books.htm)

Book chapters Multimodal Image registration for radioimmunotherapy R. Thomas, G. Flux, M. Brada, R Ott. In Radioactive isotopes in Nuclear Medicine and research. 1995. p175-182 Intralesional radiolabelled MAb in experimental tumour. R Thomas, P Carnochan, S Eccles, M Brada. For; Radioactive isotopes in Nuclear Medicine and research. Jan 1999.

1166

Empowering patients in Oncology by R Thomas, in “The Psychology of decision making” by Nova Publications 2008. The internet and Oncology by R Thomas in “The Oxford Desk Reference: Oncology” 2011. Lifestyle after Cancer by R Thomas in “The Oxford Desk Reference: Oncology” 2011.

Book reviews 'Modern developments in chemotherapy' A review for Haematology - August 1999 A combined approach to cancer management. A review for BOA magazine 2000

Talks and abstracts Olfactory sensations in Radiotherapy. Robert J Thomas, S Sagar, M Spittle. BIR Annual conference. Harrogate 1990. Abstract, British Journal of Radiology, Sept 1990. Distal Muscle Involvement in a new category of Muscular Dystrophy. R Thomas, R Goodwin-Austen. The Midlands Annual Neurological Conference. Wolverhampton, June'86. Conference proceedings. Diffusion characteristics of intralesionally administered 131I monoclonal antibody in patients with recurrent high grade glioma. R J Thomas, M Brada, P Carnochan G. Flux, N Kitchen, D Bigner, M Zalutsky. 10th International conference on Brain Tumour research. Voss, Norway. J of Neuro-Oncology. 1993. vol.15 suppl. pp.28. Localisation of uptake in radioimmunotherapy using a stereotactic head frame. R J Thomas, G Flux, M Brada. Royal College of Radiologist annual conference 1993, Warwich. Clinical Oncology October 1993. Image registration with the aid of a stereotactic head frame for radioimmunotherapeutic studies. British journal of Neurosurgery. (British Neuro-oncology group conference June 1993 ) RJ Thomas, G Flux, S Chittenden, B Cronin, R Ott, M Brada. British Journal of Neurosurgery. Dec 1993. Dosimetry of intralesional 131I monoclonal antibody therapy in patients with recurrent high grade glioma. S. Chittenden, R. Thomas, G. Flux, T. Smith, M. Brada, M. Flower, R. Ott. European Journal of Nuclear Medicine. Jan. 1994, Vol 21. p3 Multimodal Image registration for radioimmunotherapy - Surface landmark and frame based correlation in patients with recurrent high grade glioma. R. Thomas S, Chittenden,G. Flux, T. Smith, M. Brada, R. Ott. European J of Nuc Med. Jan 1994. Vol.21, pp7. Speech and language disorders in patients with high grade gliomas and its influence on survival. R Thomas, M O'Conner, S Asley, M Brada. (First congress of the European Association for Neuro-Oncology). 1994. Journal of Neuro-Oncology Vol.21, No.1. p.22.

1177

Speech and language disorders in patients with high grade gliomas and its influence on survival. (British Neuro-oncology group conference June 1994 ). R Thomas, M O'Conner, S Asley, M Brada. British Journal of Neurosurgery. Dec1994. Verbally administered Barthel Index as functional assessment in brain tumour patients. R Thomas, M Brada. (Brit. Neuro-oncology group conference ). B J Neurosurg. Dec'94. Intralesional 131I-labelled Mab therapy in patients with recurrent high grade glioma. R. Thomas , S Chittenden, G. Flux, R. Ott, M. Brada. (British Neuro-oncology group conference July1994) British Journal of Neurosurgery. Dec 1995. Intralesional 131I-labelled Mab therapy in patients with recurrent high grade glioma. R. Thomas , S Chittenden, G. Flux, R. Ott, M. Brada. (First congress of the European Association for Neuro-Oncology). 1994. Journal of Neuro-Oncology Vol.21, No.1. p.68. Acute morbidity following catheter implantation for interstitial brachytherapy and immunotherapy for glioma. P Doshi, R Thomas, R Beaney, D Thomas. (British Neuro-oncology group conference 1994) British Journal of Neurosurgery. Dec 1994. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. R Thomas, N James, A Gregor, M Brada.. (1st congress of the European Ass. for Neuro-Oncology). 1994. Journal of Neuro-Oncology Vol.21, No.1. p.45. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. N James, R Thomas, D Guerro, S Asley, A Gregor, M Brada. ( BOA 1994). British Journal of Cancer July 1994, Vol. 70. Supplement XX11. Intralesional 131-I labelled Mab therapy in patients with recurrent high grade gliomas. (BOA 1994). Thomas R, Flux G, Chittenden S, Hall A, Kitchen N, Thomas DGT, Bigner D, Zalutsky, Brada M. British Journal of Cancer July 1994, Vol. 70. Supplement XX11. 38)Verbally administered Barthel Index as functional assessment in brain tumour patients. R Thomas, L Brazil, M Brada (The first congress of the European association for Neuro-oncology April 1994). 21, (1), p.71. Monoclonal antibodies in Neuro-Oncology - a review. R Thomas. Royal College of Radiologist annual conference 1994, Warwich. Abstract. Clinical Oncology October 1994. Multimodal image registration for radioimmunotherapy. Surface Landmark and frame based correlation in patients undergoing intralesional 131-I MAb therapy for recurrent high grade glioma. (BOA 1994) Thomas R, Flux G, Chittenden C, Ott B, Brada M. British Journal of Cancer July 1994, Vol. 70. Supplement XX11. The use of multimodality imaging to monitor intralesional therapy. G. Flux, R. Thomas, S.Chittenden, T. Smith, M. Brada, M. Flower, R. Ott. ( W.F.N.M.B Sydney 1994) European Journal of Nuclear Medicine. September 1994. Stage one mixed teratoma/seminoma - outcome and patterns of failure following surveillance. Thomas R , Dearnaley D and Horwich A. (BOA 1995). British Journal of Cancer. July 1995.

1188

Distribution kinetics of radiolabelled MAbs in experimental tumours following interstitial and systemic administration. Dr R J Thomas, P Carnochan, M Brada. (ECCO 1995) Radiotherapy and Oncology. Nov. 1995. Lymphography - its role in the radiotherapy planning of carcinoma of the cervix. Thomas R, Wilkins M, Blake P. ( Conference: Brachytherapy and external beam radiotherapy for carcinoma of the cervix). February 1996. British Journal of Radiology. Carcinoma of the cervix. the role of lymphography in individualising the planning target volume. (BOA 1996). R Thomas, M Wilkins, N Hinds, P Blake. For British Journal of Radiology; 69:579 Patients attitudes towards video directed information - A multicentre study. Deary A, Kaminski E, Thomas R. The European Journal of Cancer. (ECCO) 1997. Vol. 33, Supplement 8, 1389. Do patient's want the same information as the GP? Kaminski E, Deary A, Thomas R. The European Journal of Cancer. (ECCO) 1997. Vol. 33, Supplement 8, 1391. Patient preferences for and satisfaction to a breast care nurses specialist. Shingler G, Smith S, Thomas R. European Journal of Cancer. (ECCO) 1997. Vol. 33, Supplement 8, 1397. Cancer patient education and information: Development of a new structured information package. DeZeeuz N, Bulusu R, Thomas R. EJC. (ECCO) 1997. Vol. 33, Sup 8, 1400. Patients attitudes towards an individualised filofax information system. Kaminski E, DeZeeuz N, Balusu R, Thomas R. EJC. (ECCO) 1997. Vol. 33, Sup 8, 1401. Where do patients seek additional information after a diagnosis of cancer - A multicenre survey. Shingler G, Bulusu R, Thomas R. EJC. (ECCO) 1997. Vol. 33, Sup8, 1426. Comparison of intralesional and systemically administered radiolabelled MAb in experimental tumours. R Thomas, P Carnochan, S Eccles, M Brada. E J Nuclear Med. Sup.4. Jan 1998. Video directed information - Patient satisfaction following a diagnosis of cancer. Deary A, Malone L, Jessop L, Akass C, Thomas R. Annuls of Oncology (ESM0) Volume 9, Supplement 4, pp 143. Anxiety and Depression - Effect on patients preferences for information following a diagnosis of cancer. Thomas R, Brown C, Dalton L, Welton S, Stockton D. Ann of Onc (ESM0) Vol 9, Sup 4, pp 141. Treatment of platinum-induced anaemia eith epoetin alpha: Attitudes of community and hospital based nursing staff. A Deary and R Thomas. The European J. of Cancer. Vol.35. Suppl.4. p.30 (ab. 92). Why Oncologist should provide a web site for their patients. L Dalton and R Thomas. The European Journal of Cancer. Vol.35. Suppl.4. p.46 (ab. 164). Preparatory information on video cassette significantly reduces treatment associated anxiety and depression - A randomised multicentre trial. R Thomas, M Daly, F Delorenzo

1199

The European Journal of Cancer. Vol.35. Suppl.4. p.275 (ab. 1101). Thomas R, Daly M, Dalton L, Perryman B, Stockton D. Preparatory information on video significantly improves treatment associated anxiety, depression and satisfaction - a multicentre study. JCO 1999;Supp 8 (ASCO):1570 Optimising the side effects of raltitrexed with appropriate supportive drugs: a prospective community hospital study. Thomas R, Bulusu R. EJC March 2001 vol 37, supp.2 pp119. Lyphpoma Chemotherapy – an audit of neutrpenia, dose intensity, and gcsf use in the UK. R Thomas, J.Sweetman, P Hoskins. EJC March 2001 vol 37, supp.2 pp119 Adjuvant breast cancer Chemotherapy – an audit of neutrpenia, dose intensity, and gcsf use in the UK. R Thomas and R Leonard. EJC March 2001 vol 37, supp.2 pp61 Developing and evaluating a regional patient information strategy. R Thomas, C.Lockery. EJC March 2001 vol 37, supp.2 pp 62 Measuring resposes to received information – development of a patient satisfaction questionnaire. Kaminski E, Thomas R EJC (1396) vol 37 supplement 6 October 2001 Early intervention with Epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy. ESMO 2002 Hormone therapy for breast cancer – qol, toxicity and patient preference of letrozole versus anstrozole EJC Proc EBCC 2002, Vol 38, supp 3, anstract 171 Early intervention with Epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy.’ H Thomas, R Thomas, K McAdam, J Joffe, E Sugden, S Awwad, N Bailey, A Branson. S ESMO, Nice 2002. What are the costs of not using rhEPO to treat anaemia in cancer? Robert Thomas Focus on Anaemia in cancer. Vol 3, Issue 2, 2002, Supported by Roche. Empowering patients to make informed treatment decisions; tolerability, quality of life and patients preference. A compariston of letrozole v anastrazole in a multi-centre, randomised, single blind cross over study. R. Thomas, A. Makris, 2002. EJC. 38, sup 3 S83, 171 Empowering patients to make informed treatment decisions based on tolerability, quality of life and patients preference. D Bloomfield, R Thomas, A Makris, S Godward and M Moody. 27

th ESMO Congress, Nice, France. Annals of Oncololgy, vol. 13, 2002, sup 5, 32. No. 114

Preliminary phase II results of the salicylate rich formula CV247 in patients with malignant disease. R Thomas, S Godward, M Williams, W Wassil. 27

th ESMO Congress, S 5, p 30.

Preliminary phase II results of the salicylate rich formula CV247 in patients with malignant disease. Thomas R, Godward S, Williams M, Wassif W. BOA Annual Scientific Meeting in association with BASO, Cambridge. September 2002.

Examining tolerability, quality of life and patient preference of letrozole versus anastrozole in a multicentre, randomised, single blind cross over study. Makris A, Thomas R, Bloomfield

2200

D, Godward S, Moody M. 25th

Annual San Antonio Breast Cancer Symposium. Breast Cancer Research and Treatment. Vol. 76, 2002, 265. Patient Information – patients in clinical trials are more satisfied. R. Thomas, M, Williams. 2005 EJC , Vol. 3, no.2, pp 384 (ab 1341) Can we move to a paperless information system? A Deary & R Thomas. 2005 EJC , Vol. 3, no.2, pp 460 (ab 1587). Can switching to letrozole in tamoxifen intolerant post menopausal women improve hot flushes, qol and mood? R Thomas, C Marshall, M Williams, L Walker (26

th San Antonio

Breast cancer Conference) Dec 2005. Breast Cancer Research and Treatment ab 2067. Can switching to letrozole in tamoxifen intolerant post menopausal women improve hot flushes, qol and mood? R Thomas, C Marshall, M Williams, L Walker (31

st ESMO

Conference) Oct 2006. Annals of Oncology volume 17, supplement 10 Palonestron – cost effectiveness in clinical community practice. R Thomas, , M Williams, (31

st ESMO Conference) Oct 2006. Annals of Oncology volume 17, supplement 10

Evaluating the cost effectivenss of adjuvant exemestane. ECCO Barcelona 2007 –Annals of Oncology volume 17, supplement. Nottingham breast cancer conference 2007 – Evaluating the cost effectiveness of letrozole. Conference procedings A randomised double blind randomised phase II study of salicylate compounds and lifestyle counselling in patients with arly prostate cancer. Robert Thomas, M. Williams, Simon russell, Julie gordon Roger Oakes. 2008 National Cancer Research procedings page 261. The total hospital and community costs of managing a patient with relapsed breast cancer R Thomas, M williams, C Marshall, J Glen, M Callam. 2008 National Cancer Research procedings page 226. Information satisfaction in breast and prostate cancer patients: Implications for quality of life. Davies, N.J., Kinman, G., Thomas, R.J., and Bailey, T.A. (2008) Psycho-Oncology,

published online at http://www3.interscience.wiley.com/cgi-bin/abstract/117871474/ABSTRACT.

A prospective survey of chapped lips and cold sores during chemotherapy. R Thomas, T Taylor, M Williams. Abstract ECCO 2009 vol 7, no.2 page233 sup4162 Development of a lifestyle exit tool box. R Thomas, T Taylor, M Williams. Abstract and poster ECCO 2009 EJC vol 7, no.2 page210 sup3608 Is the National activity for health referral scheme the practical solution for exercise referral for exercise rehabilitation after cancer. R Thomas, Pei Ding, M Williams. www.ncri.org.uk/ncriconference/2010abstracts/abstracts/A68.htm Omega 3 and vitamin D deficiencies are common in Cancer survivors. R Thomas, Madeleine Williams. The NCRI conference Liverpool 2011 ncriconference/2011abstracts/abstracts/B137.htm

2211

Chemotherapy induced sore lips and the use of natural and petroleum based lip balms R Thomas and Madeleine Williams. The NCRI conference Liverpool 2011 ncriconference/2010abstracts/abstracts/B131.htm Lifestyle during and after radiotherapy influences late radiotherapy toxicity. R Thomas, Mea Holm, Pat Bellamy, Jervoise Andreyev, Jane Maher. The NCRI conference Liverpool 2011

www.ncriconference/2011abstracts/abstracts/A112.htm Can the day 8 blood test be omitted for patients receiving oral vinorelbine for metastatic breast cancer. R Thomas, R Khunti, M. Williams J Glen. European Journal of Cancer. 2012 vol 48. S1 pp 392 A double blind, placebo controlled randomised trial (RCT) evaluating the effect of a polyphenol rich whole food supplement on PSA progression in men with prostate cancer - The UK National Cancer Research Network (NCRN) Pomi-T study. Accepted for ASCO 2013 R Thomas

, M Williams

1, H Sharma, A Chaudry, P Bellamy 2103 May

A polyphenol rich whole food supplement slows progression in men with prostate cancer – A double blind, placebo controlled randomised trial (The Pomi-T study). Accepted for The International Multidiscipinary Conference of supportive Care R Thomas, M Williams

1, H

Sharma, A Chaudry, P Bellamy. 2013 June